This post was originally published on this site
Investing.com – Adaptimmune stock (NASDAQ:ADAP) was locked at 20% gains after the stock climbed on announcing a tie-up with Roche (OTC:RHHBY) for commercializing cancer therapies.
The two companies will collaborate on research and development of ‘off-the-shelf’ cell therapies for up to five shared cancer targets and the development of a novel allogeneic personalized cell therapy platform.
The tie-up seeks to make cell therapies both curative and mainstream by enabling any patient to receive a T-cell product for their cancer.
Adaptimmune will use its platform to develop clinical candidates to produce T-cells. Roche’s Genentech unit will be responsible for subsequent clinical development and commercialization.
Under the terms of the agreement, Adaptimmune will receive $150 million upfront and $150 million additionally over five years. Adaptimmune may also be eligible to receive research, development, regulatory and commercial milestone payments potentially exceeding $3 billion in aggregate value.
